Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 5, 2013, Pages 524-530

  Marcellis, Rik G J ^a   Lenssen, Antoine F ^a   De Vries, Jolanda ^b,c   Drent, Marjolein ^d,e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CPRLab   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

^d GELDERSE VALLEI HOSPITAL   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Dyspnea; Exercise capacity; Fatigue; Muscle strength; Quality of life

Indexed keywords

DYSPNEA; EARLY DIAGNOSIS; EXERCISE TEST; EXERCISE TOLERANCE; FATIGUE; HUMAN; LUNG FUNCTION TEST; MUSCLE STRENGTH; MUSCLE WEAKNESS; PULMONARY HYPERTENSION; QUALITY OF LIFE; REHABILITATION CARE; REVIEW; SARCOIDOSIS; SYMPTOM;

DISABILITY EVALUATION; DISEASE MANAGEMENT; DYSPNEA; EXERCISE TEST; EXERCISE TOLERANCE; FATIGUE; HUMANS; MUSCLE WEAKNESS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS;

EID: 84881668981     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328363f563     Document Type: Review

References (56)

1. Morgenthau AS, Iannuzzi MC. Recent advances in sarcoidosis. Chest 2011; 139:174-182
2. Iannuzzi MC, Fontana Jr. Sarcoidosis: Clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305:391-399
3. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183:573-581
4. Baughman RP, Lower EE, Gibson K. Pulmonary manifestations of sarcoidosis. Presse Med 2012; 41:e289-e302
5. Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38:628-634
6. Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60:32-38
7. Wirnsberger RM, De Vries J, Wouters EF, Drent M. Clinical presentation of sarcoidosis in The Netherlands an epidemiological study. Neth J Med 1998; 53:53-60
8. Wirnsberger RM, Drent M, Hekelaar N, et al. Relationship between respiratory muscle function and quality of life in sarcoidosis. Eur Respir J 1997; 10; 1450-1455
9. Michielsen HJ, Peros-Golubicic T, Drent M, De Vries J. Relationship between symptoms and quality of life in a sarcoidosis population. Respiration 2007; 74:401-405
10. Drent M, Wirnsberger RM, De Vries J, et al. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999; 13:718-722
11. Mostard RL, Voo S, Van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011; 105:1917-1924
12. Spruit MA, Wouters EFM, Gosselink R. Rehabilitation programmes in sarcoidosis: A multidisciplinary approach. Eur Respir J 2005; 32:316-326
13. Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006; 130:989-994
14. Elfferich MD, Nelemans PJ, Ponds RW, et al. Everyday cognitive failure in sarcoidosis: The prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010; 80:212-219
15. De Vries J, Drent M. Relationship between perceived stress and sarcoidosis in a Dutch patient population. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:57-63
16. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40:255-263
17. Verbraecken J, Hoitsma E, Van der Grinten CP, et al. Sleep disturbances associated with periodic leg movements in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:137-146
18. Bourbonnais JM, Malaisamy S, Dalal BD, et al. Distance saturation product predicts health-related quality of life among sarcoidosis patients. Health Qual Life Outcomes 2012; 10:67
19. Marcellis RG, Lenssen AF, De Vries GJ, et al. Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients? Lung 2013; 191:247-256
20. Korenromp IH, Heijnen CJ, Vogels OJ, et al. Characterization of chronic fatigue in patients with sarcoidosis in clinical remission. Chest 2011; 140:441-447
21. Kabitz HJ, Lang F, Walterspacher S, et al. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest 2006; 130:1496-1502
22. Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest 2001; 120:102-108
23. Brancaleone P, Perez T, Robin S, et al. Clinical impact of inspiratory muscle impairment in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:219-227
24. Marcellis RGJ, Lenssen AF, Kleynen S, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis: A follow-up study. Lung 2013 (accepted for publication
25. Arena R, Sietsema KE. Cardiopulmonary exercise testing in the clinical evaluation of patients with heart and lung disease. Circulation 2011; 123:668-680
26. ATS/ACCP Statement on cardiopulmonary exercise testing. Joint Statement of the American Thoracic Society (ATS) and the American College of Chest Physicians (ACCP) adopted by the ATS Board of Directors and by the ACCP Health Science Policy Committee, November 1, 2001. Am J Respir Crit Care Med 2003; 167:211-277
27. Delourme J, Stervinou-Wemeau L, Salleron J, et al. Six-minute stepper test to assess effort intolerance in interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:107-112
28. Lopes AJ, De Menezes SL, Dias CM, et al. Comparison between cardiopulmonary exercise testing parameters and computed tomography findings in patients with thoracic sarcoidosis. Lung 2011; 189:425-431
29. Baydur A, Alavy B, Nawathe A, et al. Fatigue and plasma cytokine concentrations at rest and during exercise in patients with sarcoidosis. Clin Respir J 2011; 5:156-164
30. Wallaert B, Talleu C, Wemeau-Stervinou L, et al. Reduction of maximal oxygen uptake in sarcoidosis: Relationship with disease severity. Respiration 2011; 82:501-508
31. Lopes AJ, De Menezes SL, Dias CM, et al. Cardiopulmonary exercise testing variables as predictors of long-Term outcome in thoracic sarcoidosis. Braz J Med Biol Res 2012; 45:256-263
32. Delobbe A, Perrault H, Maitre J, et al. Impaired exercise response in sarcoid patients with normal pulmonary function. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:148-153
33. Miller A, Brown LK, Sloane MF, et al. Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. Chest 1995; 107:323-329
34. Kollert F, Geck B, Suchy R, et al. The impact of gas exchange measurement during exercise in pulmonary sarcoidosis. Respir Med 2011; 105:122-129
35. Medinger AE, Khouri S, Rohatgi PK. Sarcoidosis: The value of exercise testing. Chest 2001; 120:93-101
36. Barros WG, Neder JA, Pereira CA, Nery LE. Clinical, radiographic and functional predictors of pulmonary gas exchange impairment at moderate exercise in patients with sarcoidosis. Respiration 2004; 71:367-373
37. ATS. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111-117
38. Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32:296-302
39. Alhamad EH. The six-minute walk test in patients with pulmonary sarcoidosis. Ann Thorac Med 2009; 4:60-64
40. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132:207-213
41. Alhamad EH, Shaik SA, Idrees MM, et al. Outcome measures of the 6 min walk test: Relationships with physiologic and computed tomography findings in patients with sarcoidosis. BMC Pulm Med 2010; 10:42
42. Borel B, Fabre C, Saison S, et al. An original field evaluation test for chronic obstructive pulmonary disease population: The six-minute stepper test. Clin Rehabil 2010; 24:82-93
43. Dal Corso S, Duarte SR, Neder JA, et al. A step test to assess exercise-related oxygen desaturation in interstitial lung disease. Eur Respir J 2007; 29:330-336
44. Baughman RP, Lower EE. Six-minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med 2007; 13:439-444
45. Hinz A, Brähler E, Mö de R, et al. Anxiety and depression in sarcoidosis; the influence of age, gender, affected organs, concomitant diseases and dyspnea. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:139-146
46. Corte TJ, Wells AU, Nicholson AG, et al. Pulmonary hypertension in sarcoidosis: A review. Respirology 2011; 16:69-77
47. De Vries J, Drent M. Quality of life and health status in sarcoidosis: A review. Semin Respir Crit Care Med 2007; 28:121-127
48. Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013; 68:57-65
49. Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy; a randomized, double-blind pilot study. Mol Med 2013; 18:1430-1436
50. Swigris JJ, Brown KK, Make BJ, Wamboldt FS. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: A call for continued investigation. Respir Med 2008; 102:1675-1680
51. Huppmann P, Sczepanski B, Boensch M, et al. Effects of in-patient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 2012. [Epub ahead of print]
52. Kozu R, Senjyu H, Jenkins SC, et al. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2011; 81:196-205
53. Salhi B, Troosters T, Behaegel M, et al. Effects of pulmonary rehabilitation in patients with restrictive lung diseases. Chest 2010; 137:273-279
54. Kozu R, Jenkins S, Senjyu H. Effect of disability level on response to pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2011; 16:1196-1202
55. Langer D, Hendriks E, Burtin C, et al. A clinical practice guideline for physiotherapists treating patients with chronic obstructive pulmonary disease based on a systematic review of available evidence. Clin Rehabil 2009; 23:445-462
56. De Vries J, Wirnsberger RM. Fatigue, quality of life and health status in sarcoidosis. Eur Respir Mon 2005; 32:92-104